3 results
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
Primary objective:Subjective improvement of urinary incontinence (PGI-I)Secondary objectives:Objective (using stress test, padtest, bladder diaries, Sandvik score) and subjective cure of incontinence (questionnaires)Complicaties en de novo…
Objectives safety run-in: The primary objective is:• To assess the safety of i.v. teicoplanin prophylaxis three times per week with a two to three days interval in children with newly-diagnosed AML. A patient will be considered evaluable for safety…